Taken together, our findings suggest that FLT3 inhibitors in advanced stages of development or FDA approved as therapy for mutant FLT3‐positive AML, and representing a wide range of specificity for FLT3, could similarly be considered as treatments for mutant CBL‐positive leukaemia. This evidence concerns the gene FLT3 and leukemia.